Further, we explored whether S100A8/A9 blockade with a small molecule inhibitor could be used as a potential treatment against systemic inflammation and acute myocardial dysfunction in an experimental model of endotoxemia. This evidence concerns the gene IGKV1D-22 and serum lipopolysaccharide activity.